natgillin/translations-raw huggingface dataset:
A method according to claim 15 or 16, characterised in that the pain is selected from inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain and cancer pain. 
Uporaba prema zahtjevima 12 ili 13, naznačena time da bol je odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, boli zbog migrene, te boli zbog karcinoma.
is a hydrogen atom, a halogen atom, a trifluoromethyl group or a methoxy group. 
R* je atom vodika, atom halogena, trifluorometil skupina ili metoksi skupina .
is hydrogen, C1-6alkyl, heteroaryl, C3-7cycloalkyl, C1-6alkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; or C3-7cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; 
R* je vodik, C,salkil, heteroaril, Cagcikloalkil, C,.galkil supstituiran sa supstituentom odabranim od hidroksi, amino, arila i heteroarila; ili Cz-;cikloalkil supstituiran sa supstituentom odabranim od hidroksi, amino, arila i heteroarila;
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of claims 1, 2 or 3, wherein the light chain CDR1, CDR2, and CDR3 of the humanized CD37-specific binding protein consists of the amino acid sequences of SEQ ID NOS: 61, 64 and 66, respectively; and wherein the heavy chain CDR1, CDR2, and CDR3 consists of the amino acid sequences of SEQ ID NOS: 63, 65 and 68 respectively 
Humanizirani CD37-specifični vezni protein u skladu s patentnim zahtjevom 1, pri čemu se CDR1, CDR2 i CDR3 lakog lanca sastoje od sljedova aminokiselina SEQ ID NOS: 61, 64 i 66, redom; i pri čemu se CDR1, CDR2 i CDR3 teškog lanca sastoje od sljedova aminokiselina SEQ ID NOS: 63, 65 i 68, redom. Humanizirani CD37-specifični vezni protein u skladu s bilo kojim od prethodnih patentnih zahtjeva, obuhvaća:
represents a C1 to C6 alkyl group (the alkyl group optionally being substituted by a methylthio or benzyloxy group), a phenyl group, a phenyl-C1-4 alkyl group, or an indolyl-C1-4 alkyl group (the phenyl group or the indolyl group optionally being substituted by a C1 to C6 alkyl group, a halogen atom, or a C1 to C6 alkoxy group); n is a number of 0 or 1; 
predstavlja C1 do C6 alkil skupinu (alkilna skupina može po izboru biti supstituirana s metiltio, ili benziloksi skupinom), fenilnom skupinom, alkilnom skupinom fenil-C1-4, ili indolil-C1-4 alkil skupinom (fenilna skupina ili indolilna skupina po izboru su supstituirane s C1 do C6 alkil skupinom, atomom halogena, ili C1 do C6 alkoksi skupinom); n je broj 0 ili 1;
A method of screening for a substance that blocks c-met activation, said method comprising screening for a substance that binds c-met and blocks specific binding of HGF a chain to c-met. 
Postupak za pretraživanje tvari koja blokira c-met aktivaciju, naznačen time, da spomenuti postupak obuhvaća pretraživanje tvari koja veže c-met i koja blokira specifično vezanje HGF B lanca na c-met.
wherein, when the one available intra prediction mode is the planar mode, the two additional intra prediction modes include the DC mode and the vertical mode. 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja planarni način, dva dodatna unutarokovirna načina predviđanja su DC način i vertikalni način.
A bispecific antibody or antibody fragment thereof that specifically binds to IL-13 and IL-4, wherein the bispecific antibody or antibody fragment thereof competitively inhibits binding of an anti-IL-4 antibody to IL-4 by at least 50% in an immunoassay, wherein said anti-IL-4 antibody comprises the amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4, and binding of an anti-IL-13 antibody to IL-13 by at least 50% in an immunoassay, wherein said anti-IL-13 antibody comprises the amino acid sequences according to SEQ ID NO: I and SEQ ID NO: 2; or 
Izolirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-4, naznačeno time da protutijelo ili njegov fragment protutijela je humaniziran, te pri čemu protutijelo ili njegov fragment protutijela sadrži varijabilni lagani lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 3 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 4.
A compound which is 2-(3,5-Dichloro-1-oxido-pyridin-4-yl)-1-{9-difluoromethoxy-spiro[2H-1,5-benzodioxepin-3(4H),4'-tetrahydropyran]-6-yl}ethanone, or a pharmaceutically acceptable hydrate or solvate thereof, for use in the treatment of proliferative and inflammatory skin disorders such as psoriasis, epidermal inflammation, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis and eczema. 
Spoj koji je 2-(3,5-Dikloro-1-oksido-piridin-4-1l1)-1-(9-difluorometoksi-spiro[2H-1,5-benzodioksepin-3(4H),4'- tetrahidropiran]-6-il)etanon, ili farmaceutski prihvatljiv hidrat ili solvat istih, za uporabu u liječenju proliferativnih i upalnih kožnih poremećaja poput psorijaze, epidermalne upale, akni, dermatitisa, atopijskog dermatitisa, seboreičnog dermatitisa, kontaktnog dermatitisa, urtikarije, pruritisa i ekcema.
The pharmaceutical composition for use as claimed in any of Claims 1 to 10, which is in form for oral administration, subcutaneous injection, intravenous injection, or intra-articular injection. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 10, naznačen time, da je u obliku pogodnom za oralnu primjenu, za primjenu supkutanom injekcijom, za primjenu intravenoznom injekcijom ili za primjenu intraartikularnom injekcijom.
A sealable container according to any preceding embodiment, wherein the thickness of the layer of adhesive is from 20 µm to 100 µm, preferably 50 µm. 
Posuda prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je debljina sloja ljepila od 20 um do 100 um, a poželjno 50 um.
The method of claim 3 wherein said massively parallel sequencing comprises attaching DNA fragments to an optically transparent surface, conducing solid phase amplification of the attached DNA fragments to create a high density sequencing flow cell with millions of DNA clusters, and sequencing the DNA clusters by a four-color DNA sequencing-by-synthesis method employing reversible terminators with removable fluorescent dyes. 
Postupak prema zahtjevu 1, naznačen time da navedeno sekvenciranje obuhvaća vezanje DNK fragmenata za optički transparentnu površinu, provođenje umnožavanja vezanih DNK fragmenata na čvrstoj fazi da bi se stvorila sekvencirajuća protočna stanica velike gustoće s milijunima DNK klastera i sekvenciranje DNK klastera postupkom Sinteze s četverobojnim DNK sekvenciranjem, u kojem se koriste reverzibilni terminatori s uklonjivim fluorescentnim bojama.
Ry is an optionally substituted alkyl. 
R, je opcionalno supstituirani alkil.
The compound of Claim 1, wherein R5 is represented by the following formula: wherein: 
Spoj prema zahtjevu 1, pri čemu je Rsprikazan slijedećom formulom: Rome
The term “fused protein” refers to a polypeptide comprising an IL-18BP, or a viral IL-18BP, or a mutein or fragment thereof, fused with another protein, which, e.g., has an extended residence time in body fluids. 
Pojam »fuzijski protein« odnosi se na polipeptide koje obuhvaćaju IL-18BP ili viralni IL-18BP ili mutein ili njegov fragment, a koji je fuzioniran s drugim proteinom koji primjerice ima produženi polu-život u tjelesnim tekućinama: IL-18BP ili viralni IL-18BP tako mogu biti fuzionirani na drugi protein, polipeptid i si.
The physicians adapt the dose administrated at regular time intervals according to the changing needs of the patients. 
Liječnici prilagođavaju primijenjene doze u redovitim vremenskim intervalima prema promjenljivim potrebama pacijenata.
if R4 is -H, the carbon atom at the a position of the a-b bond is in the (S) configuration, R8 is -H, and R9 is -halo, then the methyl group bonded to the piperazine ring is a (R)-3-methyl group; 
gdje je metilna grupa vezana za piperazinski prsten (S)-2-metilna grupa; atom ugljika na a-b poziciji veze je u (S) konfiguraciji;
the compound of formula (XVI) is subjected to an alkylation reaction in the presence of a base and of a halogenated derivative Ra'X, Ra' being as defined in Claim 1 and X being a halogen. 
spoj s formulom (XVI) se podvrgava reakciji alkilacije u prisutnosti baze i halogeniranog derivata Ra'X, te je Ra' kako je definirano u zahtjevu 1 i X je halogen.
introduction of the at least partially solidified material inside a confined environment consisting of a rotating drum; 
uvođenje u najmanju ruku djelomično skrutnutog materijala unutar ograničenog okoliša koji se sastoji od rotirajućeg bubnja (6); gdje postupak nadalje uključuje slijedeće korake:
The method according to claim 1, wherein said administrations are separated by 2 weeks. 
Spoj FGF-18 za uporabu prema zahtjevu 1, naznačen time što navedena davanja su odvojena 2 tjedna.
abrasion resistance, opacity, colour, radiopacity, hardness, compressive strength, compressive modulus, flexural strength, flexural modulus, etc. 
otpornost na abraziju, neprozirnost, boja, radiopatija, tvrdoća, kompresivna jakost, kompresivni modul, jakost na izvijanje, modul za izvijanje itd.
It is an object of the present invention to provide a mixing member for blenders, designed to eliminate the aforementioned drawbacks, and which is also cheaper to produce. 
Cilj je predmetnog izuma da dade članak za miješanje kod miješalica, dizajniran da ukloni gore navedene nedostatke i koji je također jeftiniji za proizvodnju.
Building and construction element according to claim 1, at least one of the outside cover layers comprising paper. 
Građevni i konstrukcijski element prema zahtjevu 1, naznačen time da se pokrovni sloj (2) sastoji od papira.
contacting the A9-tetrahydrocannabinol from step (b) with a non-polar organic solvent and optionally its enantiomer to form the first composition. 
(c) kontaktiranje trans-(+)-A'-tetrahidrokanabinola iz koraka (b) sa trans-(-)-A'-tetrahidrokanabinolom i nepolarnim organskim otapalom da formiraju prvi sastav.
The process of claim 9, wherein the at least two peptide fragments of PCSK9 are administered in an amount of 0.1 ng to 10 mg per dose to the subject. 
Cjepivo prema zahtjevu 9, naznačeno time, da se najmanje dva fragmenta od PCSKO daju pojedincu za jednu dozu u količini od 0,1 ng do 10 mg, poželjno od 1 ug do 500 ug.
conjugating a cytotoxic agent to the cell-binding agents having linkers bound thereto in the purified first mixture by reacting the cell-binding agents having linkers bound thereto with a cytotoxic agent in a solution having a pH of about 4 to about 9 to prepare a second mixture comprising (i) cell-binding agent chemically coupled through the linker to the cytotoxic agent, (ii) free cytotoxic agent, and (iii) reaction by-products; and 
konjugacije maitanzinoida sa antitijelima koja imaju za sebe vezane linkere u pročišćenoj prvoj smjesi putem reakcije antitijela koja imaju za sebe vezane linkere sa maitanzinoidom u otopini koja ima pH od 4 do 9 da bi se pripremila druga smjesa koja sadrži (i) antitijelo kemijski spojeno preko linkera za maitanzinoid, (ii) slobodan maitanzinoid i (iii) sporedne proizvode reakcije, i
It is a embodiment of the present invention that the combination, product, kit of parts or package comprise (b) an M3 antagonist of the invention and (a) a corticosteroid as the sole active compounds. 
U jednom od utjelovljenja predmetnog izuma kombinacija, proizvod, pribor s dijelovima ili paket sadrže (b) M3 antagonist sukladno predmetnom izumu i (a) B2 agonist kao jedine djelatne spojeve.
The formulation according to any of aspects 26 to 37, which has a pH of 5.5 or 7.0. 
Formulacija prema zahtjevu 8, naznačena time što je pomoćna tvar saharid, nereducirajući šećer i/ili poliol.
The process of claim 2, wherein the process comprises purifying oxycodone HCl. Purified oxycodone free base prepared according to the process of claim 2, wherein the ratio of 8 a, 14-dihydroxy-7,8-dihydrocodeinone to oxycodone free base is 0.04% or less as measured by HPLC. 
Farmaceutski oblik doziranja prema patentnom zahtjevu 11, naznačen time da je u postupku sastav baze oksikodona koji sadrži 8,14-dihidroksi-7,8-dihidrokodeinon reagirao s klorovodičnom kiselinom u količini većoj od 1.0 molarnog ekvivalenta u usporedbi sa slobodnom bazom oksikodona.
A light source as claimed in claim 1, wherein the body is a plasma crucible is of circular cross-section and is dimensioned for a half wave to extend diametrically within it. 
Svjetlosni izvor u skladu s onim iz patentnog zahtjeva 1, patentnog zahtjeva 2 ili patentnog zahtjeva 3, naznačen time, da plazmena retorta ima kružni poprečni presjek i dimenzije koje omogućuju da se poluval širi dijametralnu unutarnje.
wherein the wing is non-symmetrical about a line extending across the neutral aerofoil section perpendicularly to the neutral mean camber line, the wing being: 
pri čemu je krilo asimetrično oko linije koja se pruža uzduž neutralnog dijela zračnog profila okomito na neutralnu srednju liniju nagiba, a krilo:
The umbrella as recited in claim 1, wherein an end of the central holding element oriented toward the umbrella strut elements is substantially pyramid-shaped, a cross-sectional area of the central holding element forms a base of a pyramid, and a respective contact surface of the central holding element and a respective umbrella strut element is situated on a respective side surface of the pyramid. 
Kišobran kao što je navedeno u patentnom zahtjevu 1, naznačen time da je završetak središnjeg elementa držača orijentiran prema potpornim elementima kišobrana realiziran uglavnom u obliku piramide, površina poprečnog presjeka središnjeg elementa držača tvori osnovicu piramide, te je odgovarajuća dodirna površina središnjeg elementa držača i odgovarajućeg potpornog elementa kišobrana smještena na odgovarajućoj bočnoj površini piramide.
A is selected from the group consisting of 
A je odabrana iz skupine koju čine
Particularly advantageously, the flow-through housing takes the external form of a cube or a cylinder, so that, to increase the performance in an easy way, multiple identical cubes or cylinders and/or, to enhance the fluid treatment, cubes or cylinders with other treatment elements, such as activated carbon, particle filters or ion exchangers, can be combined with one another to form cuboids or cylinders in series with one another of a greater length or height. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što se, radi poboljšavanja izvedbe, više istovjetnih kuboida ili valjaka, i/ili radi proširivanja obrade fluida, kuboide ili valjke može kombinirati s drugim elementima za obradu, poput aktivnog ugljena, čestičnih filtara ili ionskih izmjenjivača kako bi se dobilo kuboide ili valjke s većim omjerom duljina/visina.
Device according to claim 9, characterised in that an inner surface of said containment portion (112) is coated by overmoulding with a layer (120) of non-stick material in the manufacturing step. 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što je unutarnja površina navedenog dijela za držanje (112) obložena prekalupljenim slojem (120) neljepljivog materijala u koraku proizvodnje.
A process for the provision of a compound of Formula I said process comprising: 
PATENTNI ZAHTJEVI 5 1. Postupak dobivanja spoja Formule I
The antibody according to claim 15 wherein the corticosteroid consists of methylprednisolone and prednisone. 
Antitijelo prema zahtjevu 15, naznačeno time, da se kortikosteroid sastoji od metilprednisolona i prednisona. tr>
The medicament for use according to any one of claims 1 or 3-7 for use in reducing frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis. 
Lijek za uporabu prema bilo kojem od patentnog zahtjeva 1 ili patentnih zahtjeva 3-8, naznačen time, da jest za uporabu u smanjivanju učestalosti relapsa kod pacijenta koji pati od relapsno remitirajuće multiple skleroze.
at least 80% (at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5%) of the polypeptides retain their binding activity (as assessed by ELISA and/or Biacore) to at least one of their targets after storage at 37±5°C up to 2 weeks (preferably at least 4 weeks, more preferably at least 6 weeks, most preferably at least 8 weeks or more) compared to the binding activity prior to storage; and/or 
- najmanje 80% polipeptida zadržava svoju aktivnost vezanja na barem jedan od svojih ciljeva nakon skladištenja na temperaturi od 37+5*C do najmanje 2 tjedna (poželjno najmanje 3 tjedna, najmanje 5 tjedana, najmanje 2 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više) u usporedbi s aktivnošću vezanja prije skladištenja, navedena aktivnost vezanja izmjerena je pomoću testa ELISA i/ili testa Biacore; i/ili -
reacting the gaseous chlorine and gaseous hydrogen in the presence of an activated carbon catalyst to form gaseous hydrogen chloride; and 
reakciju plinovitog klora i plinovitog vodika u prisutnosti katalizatora s aktivnim ugljenom da se dobije plinoviti klorovodik; i
The residue was purified on silica gel (10% ethyl acetate/ dichloromethane) to give compound 22 as a yellow solid. 
Ostatak se pročišćava na silikagelu (10% etil-acetat/ diklormetan) čime se dobiva spoj 22 kao žuta krutina.
The tremor inhibitory action of 60 mg/kg tolperisone alone and in the presence of dextromethorphan at different ratios (20:1; 10:1 and 5:1). 
Djelovanje samog tolperisona od 60 mg/kg i u prisutnosti dekstrometorfana kod različitih omjera (20:1; 10:1 i 5:1) na inhibiciju tremora.
A bicontinuous micro-emulsion including a hydrophilic phase, a hydrophobic phase and a surface-active substance; as well as a catalyst in at least one of the hydrophilic phase and hydrophobic phase, which catalyst has been generated in situ in a precipitation reaction by reduction of a metal complex, said bicontinuous micro-emulsion being obtainable by mixing (i) a first bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase and a surface-active agent, to which bicontinuous micro-emulsion a salt or a metal complex of a catalyst material is supplied to the hydrophilic phase, and a (ii) second bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase and a surface-active agent, further containing a reducing material, wherein upon mixing a precipitation reaction takes place on which the catalyst is formed. 
Bikontinuirana mikroemulzija koja uključuje hidrofilnu fazu, hidrofobnu fazu 1 površinski reaktivnu supstancu; kao i katalizator u barem jednoj od hidrofilne faze i hidrofobne faze, koji je katalizator generiran in situ u reakciji taloženja redukcijom metalnog kompleksa, navedenu bikontinuiranu emulziju moguće je dobiti miješanjem (i) prve bikontinuirane mikroemulzije koja sadrži hidrofilnu fazu, hidrofobnu fazu i površinski aktivni agens, na koji bikontinuiranu emulziju se dovodi kompleks soli ili metala katalitičkog materijala u hidrofilnoj fazi, i (ii) drugu bikontinuiranu mikroemulziju koja sadrži hidrofilnu fazu, hidrofobnu fazu i površinski aktivni agens, nadalje sadrži reducirajući materijal, pri čemu miješanjem dolazi do reakcije taloženja u kojoj se formira katalizator.
derived from or associated with thyroid cancer, neuroendocrine cancer, glioblastoma, a female gynecological cancer, any combinations thereof or a metastasis thereof; or 
potječe od ili je povezan s rakom štitnjače, neuroendokrinim rakom, glioblastomom, ženskim ginekološkim rakom, bilo kojom kombinacijom istih ili metestazom istih; ili
The compound of claim 11, wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Uporaba prema patentnom zahtjevu 11, naznačena time što su kognitivni poremećaji i bolesti izabrani iz grupe koju čine Alzheimer-ova bolest, oblici gubitka pamćenja i gubitak pamćenja uzrokovan starošću.
The compound for use of claim 3, wherein the compound is used in a therapeutically effective amount ranging from about 0.1 mg/kg to about 300 mg/kg. 
Spoj za primjenu u skladu s patentnim zahtjevom 3, naznačen time, da se spoj koristi u terapijski učinkovitoj količini od oko 0,1 mg / kg do oko 300 mg / kg.
The compound for use in treating a medical condition related to CXCR4 according to claim 10, wherein the compound is in a composition formulated as eye drop, ointment, injectable fluid, microparticles, or sustained release form. 
Spoj za uporabu u liječenju medicinskog stanja povezanog s CXCR4 prema zahtjevu 10, naznačen time da je spoj u pripravku formuliranom kao kapi za oči, pomast, injekcijska tekućina, mikročestice, ili oblik s produljenim otpuštanjem.
Of course the threshold may be accommodated by the system manager. 
Naravno da voditelj sustava može prilagoditi prag.
The compound of claim 11 having an X-ray diffraction pattern, expressed in terms of 2 θ angles, that shows peaks at 6.0, 7.5, 8.5, 12.3, 16.0, 17.0, 18.0, 18.2, 18.7, 23.2 and 25.2 ± 0.2 degrees. 
Spoj u skladu s patentnim zahtjevom 11, naznačen time što ima uzorak difrakcije rendgenskih zraka, dan u terminima kutova 26, sa signalima na 6,0, 7,5, 8,5, 12,3, 16,0, 17,0, 18,0, 18,2, 18,7, 23,2 125,2 + 0,2 stupnja.
By introducing the line section 32 into the clamping block 50 the flanges 34, 35 are pressed together tightly closed, so that a liquid-tight seal is obtained. 
Uvođenjem dijela cijevi 32 u blok za stezanje 50, prirubnice 34, 35 su zajedno čvrsto pritisnute zatvorene, tako da se postiže nepropusno brtvljenje.
a mammalian cell, wherein the mammalian cell is an Expi293F cell, a CHO cell, a 293T cell, or a NSO cell, preferably wherein the mammalian cell is an Expi293F cell. 
stanici sisavaca, s time, da je stanica sisavaca stanica Expi293F, stanica CHO, stanica 293T ili stanica NSO, preferirano s time, da stanica sisavaca je stanica Expi293F.
The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference. A polypeptide comprising a first biologically active moiety and a second biologically active moiety, wherein the polypeptide comprises a formula selected from the group consisting of: A-F1-B-P1-L-P2-F2 and A-F1-P1-L-P2-B-F2 in linear sequence from amino to carboxy terminus, 
Polipeptid prema patentnom zahtjevu 2 ili 3, naznačen time što polipeptid ima formulu izabranu iz skupine koja se sastoji od: A-F1-B-P1-L-P2-F2; A-F1-P1-L-P2-B-F2; A-F1-P1-L-P2-F2; i FI-P1-L-P2-B-F2; u linearnoj sekvenci od amino do karboksi terminalnog kraja, i pri čemu A je barem jedan biološki aktivan dio;
The apparatus of claim 1, wherein the intra prediction mode is coded using an upper intra prediction mode and a left intra prediction mode, and when the upper intra prediction mode or the left intra prediction mode is unavailable, the upper intra prediction mode or the left intra prediction mode is set to a DC mode. 
Uređaj prema zahtjevu 1, naznačen time da je način unutarokvirnog predviđanja kodiran korištenjem gornjeg načina unutarokvirnog predviđanja 1 lijevim načinom unutarokvirnog predviđanja, i kada je gornji način unutarokvirnog predviđanja ili lijevi način unutarokvirnog predviđanja nedostupan, gornji način unutarokvirnog predviđanja ili lijevi način unutarokvirnog predviđanja je namješten na DC način.
• the parenteral formulation is a sterile aqueous solution further comprising salts or monosaccharides in a quantity to make the formulation isotonic with blood. 
* parenteralna formulacija je sterilna vodena otopina koji dodatno sadrži soli ili monosaharide u količini kako bi formulacija bila izotonična s krvlju.
Since the termination module 45 rotates unitarily with or in unison with the cable spool 37, the second end of the subscriber cable 22 can be paid out without the first end of the subscriber cable 22 being pulled out of the termination module 45 . 
Postupak izvlačenja optičkog kabela odmotavanjem (22, 122) 1z kutije sa optičkim kabelom prema Zahtjevu 1, gdje se završni modul (45, 149) nalazi na završetku osovine kalema (37, 137) kabela.